View of Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database.

Return to Article Details Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database. Download Download PDF